Misplaced Pages

Litifilimab

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Monoclonal antibody
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)
Pharmaceutical compound
Litifilimab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetBDCA2
Identifiers
CAS Number
PubChem CID

Litifilimab is an investigational drug being evaluated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. It is an anti-BDCA2 monocolonal antibody.

References

  1. "Litifilimab - Biogen". AdisInsight. Springer Nature Switzerland AG.
  2. Cho SK, Vazquez T, Werth VP (May 2023). "Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus". Expert Opinion on Investigational Drugs. 32 (5): 345–353. doi:10.1080/13543784.2023.2212154. PMID 37148249. S2CID 258547912.
  3. Cho YM, Furie R (October 2023). "The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus". Immunotherapy. doi:10.2217/imt-2023-0086. PMID 37877249. S2CID 264448220.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: